Skip to main content
OpenTrials
Completed

NCT Number: NCT02180074

Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease

Cardiovascular disease which includes coronary artery disease and peripheral artery disease remains the leading cause of death among women in the United States. The impact of cardiovascular in women was not recognized by clinicians for a long time. It is now evident that, women suffer the consequences of cardiovascular at rates at least as high as those observed in men but there are still major gaps in our understanding this disease in women. Hydrogen sulfide (H2S), a gaseous mediator plays an important role in the cardiovascular system. Research has demonstrated it's critical role in animal ischemia reperfusion models. Hydrogen sulfide exists in distinct biological pools in blood. Recently, the Kevil lab has pioneered the development of new analytical techniques for accurate measurement of all biological pools of H2S. By measuring these distinct pools of H2S in women with and without cardiovascular disease the investigators hope to further understanding of role of H2S in pathophysiology of cardiovascular disease. This research will help to assess the ability of H2S and its distinct biological pools to potentially be a diagnostic marker or a therapeutic target for cardiovascular disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

Female

Study type

Observational

Primary location

LSUHSC

Shreveport, Louisiana, 71103, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients presenting to the cardiac catheterization laboratory for coronary or peripheral angiography.
  • Females,Age>40years

Exclusion criteria

  • Inability to provide informed consent.
  • STelevationmyocardialinfarction.
  • Cardiogenicshock.
  • ABI >1.4 (indicative of non-compressible vessel needing further evaluation to diagnose PAD), unless documented known PAD. 4. Non-atheroscleroticPAD(e.g.Buerger'sdisease). 5. Enrolment in another clinical trial with use of experimental therapeutic agents.

Treatment and study plan

Primary outcomes

  1. Free Sulfide, Bound Sulfide and Acid Labile Sulfide

    Time frame: 1 year

    Unit of Measure: nMol

Sponsors and collaborators

Lead sponsor

Louisiana State University Health Sciences Center Shreveport

Other

Registry information

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Jul 2, 2014
Registry last updated
Sep 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.